ARRY


Array BioPharma (ARRY): More Fuel for the Bulls

There’s a new FDA-approved melanoma medication on the scene. Today, the U.

Are New Drug Approvals Right Around the Corner for Trevena (TRVN) and Array Biopharma (ARRY)?

Analysts chime in across the Street on potential approval odds for TRVN’s pain management drug oliceridine and ARRY’s cancer combination therapy of encorafenib with binimetinib.

Cowen Bets on Array BioPharma (ARRY) Ahead of Upcoming PDUFA Date

Array Biopharma (NASDAQ:ARRY) shares started the day lower in the wake of disappointing results from competitor Exelixis (NASDAQ:EXEL). Exelixis announced that its metastatic colorectal cancer (mCRC) treatment did …

Array Biopharma Inc’s (ARRY) BRAF-Mutant Melanoma Combo Treatment Gets a PDUFA Date; Cantor Chimes In

Analyst expected NDA acceptance- but believes the FDA news importantly lowers regulatory risk for ARRY.

Cantor Now Sees Bigger Market Opportunity for Array Biopharma Inc’s (ARRY) Binimetinib/Encorafenib Following ESMO Presentation

Forecasting a potential $500 million yearly sales opportunity ahead, the analyst lifts price target on Array.

Cowen Sees Array Biopharma Inc (ARRY) Share Weakness as Attractive Despite NDA Loss

Array Biopharma Inc (NASDAQ:ARRY) shares are dipping almost 8% after the discouraging news broke that the biotech firm has decided to withdraw its …

Cantor Reiterates Positive Stance on Array Biopharma Inc (ARRY)

In a research report published Friday, Cantor analyst Mara Goldstein reiterated an Overweight rating on shares of Array Biopharma Inc (NASDAQ:ARRY) with a …

Cowen Boosts Price Target on Array Biopharma Inc (ARRY) Amid Stellar Momentum

Array Biopharma Inc (NASDAQ:ARRY) shares were soaring 17% yesterday on back of a second fiscal quarter update that has given investors signs of …